Bio-Aktie gestern -80%??? - 500 Beiträge pro Seite

[flotti]

Hey Leute!!!

Wer weiß was über die Aktie CONNECTIS?
Sie ist gestern von 25$ auf ca. 5$ gefallen!!! Wird diese Aktie auch in Deutschland gehandelt?
Wer hat eine WPKN oder Nasdaq-Kürzel?

Danke

[ragnarok]

Die Aktie heisst Connetics, WKN 899160.
Die Antwort gibts u.a. bei Yahoo Finance:

Monday October 9 4:35 PM ET
Connetics Plunges After Drug Fails Trial

NEW YORK (Reuters) - Shares of Connetics Corp. (NasdaqNM:CNCT -
news) tumbled nearly 77 percent Monday on news that the
biotechnology company had dropped plans to seek approval of a drug to
treat the disease scleroderma after the medication failed to meet its
primary goals in clinical trials.

Connetics shares tumbled $20-3/16 to $5-5/16 in trade on the Nasdaq
stock market.

On Sunday, the Palo Alto, Calif.-based biotech company said a Phase
III trial for the drug Relaxin, which involved 239 patients with stable,
moderate and severe diffuse scleroderma of less than five years`
duration, failed to reach its primary goals for treatment of the rare skin
disease.

Scleroderma is a degenerative disease in which there is scarring to the
skin, joints and internal organs. Typical symptoms include thickening and
swelling of the ends of the fingers. The cause of the disease is unknown.

The trial results also dragged down shares of Britain`s leading
biotechnology company, Celltech Group Plc (CTP.L), which fell more than
five percent Monday. Celltech, which acquired Relaxin when it bought
Medeva Pharmaceuticals Inc. last year, was developing the treatment
with Connetics. But the results were not as great a setback for Celltech
as for Connetics because Relaxin is not one of Celtic`s core products,
according to industry analysts.

Connetics` stock was downgraded by two brokerage houses before the
stock market opened this morning.

UBS Warburg analyst Ross Taylor cut his rating to ``hold`` from ``buy`` and
lowered his price target on the stock to $10 from $24. Taylor said in a
note that he was still confident Connetics has ``sufficient cash and
securities to sustain its operations for several years.``

``On a positive note, the (Relaxin) trial did provide important additional
data on the biological activity of the drug, and Connetics plans to
continue its development program for Relaxin in other diseases like
peripheral vascular disease, infertility, congestive heart failure and
coronary artery disease,`` Taylor said.

Lehman Bros. cut its rating on Connetics to ``neutral`` from ``outperform``
and lowered its 12-month price target to $14 from $48. Lehman said the
price target was ``based solely on the value of the (company`s)
dermatology business,`` which it said is on target with an estimated $28.4
million in revenues in 2001 and a growth rate of 30 percent.

On Sunday, Connetics Chief Financial Officer John Higgins
characterized the Relaxin trial as a ``bump in the road`` that could occur
in any drug`s development. He said the trial had produced a lot of
positive data that could lead to Relaxin being tested for treating other
diseases.

``Certainly, it`s a disappointment,`` Higgins told Reuters. ``(But) the hurdle
for success was pretty high in this trial ... and now we have so much data
on how this drug might work in other diseases.``

He said other areas for future development of Relaxin could include
cardiovascular illnesses and infertility.

Connetics said detailed results of the trial would be presented on Oct. 24
at the Relaxin 2000 Conference in Broome, Australia.

[flotti]

Danke!!!

Schreibfehler könne eben einen aus der Bahn werfen!!!


Und ein Kauf oder zu heiß?


Flotti

[[e-mail]]

gibts das auch auf deutsch?